Premium
Alpha‐2b‐interferon as single therapy for patients with chronic myeloid leukemia relapsing after T‐cell depleted allogeneic bone marrow transplantation
Author(s) -
Arcese W.,
Mauro F. R.,
Screnci M.,
Alimena G.,
Iori A. P.,
Cuia M. R.,
Coco F. Lo,
Montefusco E.,
Fazi P.,
Mandelli F.
Publication year - 1990
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1990.tb00904.x
Subject(s) - medicine , bone marrow , transplantation , gastroenterology , myeloid , blast crisis , myeloid leukemia , alpha interferon , chemotherapy , leukemia , surgery , immunology , interferon
20 CML patients with hematological (5 pts) or only cytogenetic (15 pts) relapse occurring after allogeneic BMT have been treated with alpha‐2b‐interferon (IFN) at a starting dose of 5 times 10 6 IU/m 2 , subcutaneously, three times a week. All 5 patients with hematological relapse achieved hematological remission without reduction of bone marrow Ph1‐positive cells. With a median follow‐up of 43 months (range 6–48) from the hematological relapse, 3 patients are alive and 2 patients died from non‐lymphoid blast crisis. 7 out of 15 patients with only cytogenetic relapse remain in hematological remission at a median of 37 months (range 3–45) from cytogenetic relapse, with 2 patients achieving complete cytogenetic remission confirmed at the molecular level by disappearance of the bcr rearranged band. With a median follow‐up of 21 months (range 6–46), 8 patients progressed from cytogenetic to hematological relapse: 4 patients died from blast crisis and the other 4 patients are currently alive in chronic phase. For the 15 patients, the actuarial survival from BMT is 71% at 5 years.